Oppenheimer Comments On Unfounded Jarden Weakness

According to Oppenheimer, Jarden JAH weaknesses are unfounded. Oppenheimer said that it believes the recent weakness in the shares of JAH since reporting solid 1Q results in late April—in our view largely predicated on top-line fears—are unfounded. “Further, we would use this weakness as a buying opportunity ahead of our upcoming Oppenheimer Consumer Conference later this month, where management is expected to provide an upbeat business assessment, while valuation remains compelling.” Jarden closed yesterday at $32.04.